Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...

The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Note to readers: The Daily Edition will not be published Dec. 23 through Jan. 1. Look for it again in your inbox on Jan. 2.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told ...